Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with Phase 3 Study

Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.

Karuna Therapeutics, Inc. is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease. The study aims to assess the safety and efficacy of KarXT in adults with mild to severe Alzheimer’s Disease (AD) experiencing moderate to severe psychosis related to AD. This research is significant as it addresses a critical need for effective treatments for psychosis in AD patients.

The intervention being tested is KarXT, an experimental drug designed to treat psychosis in Alzheimer’s patients. It is compared to a placebo to evaluate its effectiveness and safety.

The study follows an interventional design with a randomized allocation and a parallel intervention model. It employs a quadruple masking approach, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment assignments. The primary purpose of the study is treatment-focused.

The study began on September 26, 2024, and the latest update was submitted on June 24, 2025. These dates are crucial for tracking the progress and current status of the study, which is still recruiting participants.

This update may positively influence Karuna Therapeutics’ stock performance and investor sentiment, as successful results could position KarXT as a leading treatment for psychosis in Alzheimer’s Disease. Investors should also consider the competitive landscape, as advancements in this area could impact market dynamics.

The study is ongoing, and further details are available on the ClinicalTrials portal.